Nanocan Therapeutics Corporation is an early-stage
biotechnology company developing novel drug-delivery nanotechnology for more precise and targeted treatment
of cancer and respiratory diseases. More precise local treatment can unlock local immune-driven potential and
significantly reduce the risk of side effects. Through our partnerships with leading academic research
institutions, we are rapidly developing new shorter and efficient combination therapies to help improve the
lives of patients and improve global access to care.
Nanocan is committed to making its disruptive innovations for shorter one-day delivery of combinations of radiotherapy and immunotherapy, available to cancer patients in Low and Middle-Income Countries (“LMICs”), starting with countries in Africa through our strong network of leading US and UK universities, as well as partners in Nigeria, Kenya, South Africa. Nanocan is simultaneously pursuing clinical trials and regulatory approvals in both the U.S. and certain African countries.
To improve global access to efficient cancer care, novel shorter combination treatments are needed, especially for advanced stages of disease. We want to drive innovation and provide novel therapies to cancer patients world-wide and make them accessible with shorter interventions and lower costs.
THERAPEUTIC AREAS OF FOCUS
With the Company’s novel therapeutics, Nanocan seeks to transform treatments for solid cancers. Nanocan’s initial products for rollout will target prostate cancer, pancreatic cancer, and cervical cancer:
Prostate Cancer: One of the most common forms of cancer. According to the American Cancer Society,
about 1 in 8 men will be diagnosed with prostate cancer in their lifetimes and approximately 35,000 men will die from the disease in 2022.
Prostate cancer is the second leading cause of death of men in the U.S. In 2020, an estimated 375,000 people died from prostate cancer worldwide.
Pancreatic Cancer: One of the deadliest forms of cancer with limited treatment options. According to the National Cancer Institute, the 5-year relative survival rate for pancreatic cancer patients is 10%. It’s estimated there will be 57,600 new pancreatic cancer cases in the U.S. in 2020, with over 47,000 deaths. The World Health Organization (WHO) estimates there were 458,000 new cases of pancreatic cancer globally in 2018, with 432,000 deaths. Nanocan has preclinical data showing promising results for a potential safe and effective therapeutic for this form of cancer.
Cervical Cancer: When detected at an early stage, the 5-year survival rate for cervical cancer is over 90%. Low and Middle Income Countries (“LMICs”) and other low-resource settings have inadequate cervical cancer screening which leads to higher cancer disparities and deaths. More over, HIV/AIDS infection, still very common, increases the risk and aggressiveness of cervical cancer. According to the WHO over 570,000 persons will be diagnosed with cervical cancer worldwide with over 311,000 deaths in 2020. Nanocan has partnerships with leading cancer treatment centers in Africa and is mapping out multicenter clinical trials for cervical cancer in LMICs.
Nanocan’s next tier of products for rollout will target:
NANOCAN’S LEADERSHIP TEAM